IL-12 and IL-23 in health and disease

Expert Review of Clinical Immunology

Volumn 4, Issue 3, 2008, Pages 301-303

  Stetsko, Dawn ^a   Sauder, Daniel N ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ANTIINFLAMMATORY AGENT; CNTO 1275; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 23; MESSENGER RNA; STA 5326;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CLINICAL TRIAL; CROHN DISEASE; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN TARGETING; PSORIASIS; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; TRANSCRIPTION REGULATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 46149125283     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.3.301     Document Type: Editorial

References (15)

1. Goriely S, Goldman M. The interleukin-12 family: new players in transplantation immunity? Am. J. Transplant. 7, 278-284 (2007).
2. Kreymborg K, Bohlmann U, Becher B. IL-23: changing the verdict on IL-12 function in inflammation and autoimmunity. Expert Opin. Ther. Targets 9(60), 1123-1136 (2005).
3. Murphy CA, Langrish CL, Chen Y et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198(12), 1951-1957 (2003).
4. McGovern D, Powrie E The IL23 axis plays a key role in the pathogenesis of IBD. Gut 56, 1333-1336 (2007).
5. Hunter C. New IL-12 family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531 (2005).
6. Watford W, Moriguchi M, Morinobu A, O'Shea J. The biology of IL-12: coordinating innate and immune responses. Cytokine Growth Factor Rev. (14), 361-368 (2000).
7. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. (202), 96-105 (2004).
8. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL12 and IL23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202, 139-156 (2004).
9. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3(2), 133-146 (2003).
10. Trinchieri G, Pflanz S, Kastelein RA, The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity (19), 641-644 (2003).
11. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. (27), 17-23 (2006).
12. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201(2), 233-240 (2005).
13. Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin 12 antibody for active Crohn's disease. N. Engl. J. Med. 351(20), 2069-2079 (2004).
14. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis results of a randomized, placebo-controlled, Phase 2 trial. Arch. Dermatol. 144(2), 200-207 (2008).
15. Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/ 23 monoclonal antibody for psoriasis. N. Engl. J. Med. (356)6, 580-592 (2008).